help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH

This version published online on September 22, 2005
Endocrinology, doi:10.1210/en.2005-0518
A more recent version of this article appeared on January 1, 2006
This Article
Right arrow Author Manuscript (PDF)
Right arrow All Versions of this Article:
147/1/70    most recent
Author Manuscript (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nardelli, B.
Right arrow Articles by Moore, P. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nardelli, B.
Right arrow Articles by Moore, P. A.

Submitted on May 2, 2005
Accepted on September 13, 2005

Osteostat/TNFSF18 inhibits osteoclastogenesis and is selectively expressed by vascular endothelial cells

Bernardetta Nardelli, Liubov Zaritskaya, William McAuliffe, Yansong Ni, Clint Lincoln, Yun Hee Cho, Charles E. Birse, Wendy Halpern, Stephen Ullrich, and Paul A. Moore*

Human Genome Sciences, Inc., Rockville MD, 20850

* To whom correspondence should be addressed. E-mail: paul.moore{at}celera.com.

Vascular endothelial cells participate to the process of bone formation through the production of factors regulating osteoclast differentiation and function. Here we report the selective expression in primary human microvascular endothelial cells (HMVEC) of Osteostat/TNF Superfamily 18 (TNFSF18), a ligand of the TNF superfamily. Osteostat protein is detectable in HMVEC and is highly upregulated by interferon (IFN)-{alpha} and IFN-{beta}. Moreover, an anti-Osteostat antibody strongly binds to the vascular endothelium in human tissues, demonstrating that the protein is present in the endothelial cell layers surrounding blood vessels. Functional in vitro assays were used to define Osteostat involvement in osteoclastogenesis. Both recombinant and membrane bound Osteostat inhibit differentiation of osteoclasts from monocytic precursor cells. Osteostat suppresses the early stage of osteoclastogenesis via inhibition of macrophage colony-stimulating factor (M-CSF)-induced receptor activator of NF-{kappa}B (RANK) expression in the osteoclast precursor cells. This effect appears to be specific for the differentiation pathway of the osteoclast lineage, since Osteostat does not inhibit lipopolysaccharide (LPS)-induced RANK expression in monocytes and dendritic cells, or activation-induced RANK expression in T cells. These findings demonstrate that Osteostat is a novel regulator of osteoclast generation and substantiate the major role played by the endothelium in bone physiology.


Key words: osteoclasts • TNF • endothelial cells







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2005 by The Endocrine Society